Dottikon Es Holding AG
SIX:DESN

Watchlist Manager
Dottikon Es Holding AG Logo
Dottikon Es Holding AG
SIX:DESN
Watchlist
Price: 347.5 CHF -0.71% Market Closed
Market Cap: 4.9B CHF

Dottikon Es Holding AG
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Dottikon Es Holding AG
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Dottikon Es Holding AG
SIX:DESN
Operating Income
CHf137.1m
CAGR 3-Years
21%
CAGR 5-Years
26%
CAGR 10-Years
35%
Sika AG
F:SIKA
Operating Income
CHf2.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Clariant AG
SIX:CLN
Operating Income
CHf420m
CAGR 3-Years
-8%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Givaudan SA
SIX:GIVN
Operating Income
CHf1.4B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
6%
Ems Chemie Holding AG
SIX:EMSN
Operating Income
CHf543.9m
CAGR 3-Years
-5%
CAGR 5-Years
0%
CAGR 10-Years
2%
D
DSM-Firmenich AG
AEX:DSFIR
Operating Income
€560m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Dottikon Es Holding AG
Glance View

Market Cap
4.8B CHF
Industry
Chemicals

Dottikon Es Holding AG stands as one of Switzerland's understated gems in the realm of fine chemicals and pharmaceuticals. Born from Switzerland's rich tradition of precision and quality, the company operates primarily in the realm of exclusive synthesis, tailored to meet the stringent demands of the pharmaceuticals industry. At its core, Dottikon specializes in hazardous chemical reactions, priding itself on an ability to transform complex chemical processes into high-quality results. This specialization provides a competitive edge, allowing Dottikon to focus on developing innovative and complex molecules which serve as active pharmaceutical ingredients (APIs). It's a business model that not only underscores the company's technical expertise but also its commitment to safety and environmental stewardship, given the heightened risks associated with hazardous materials. Revenue for Dottikon is chiefly generated from strategic partnerships with major pharmaceutical companies. By offering a unique combination of research and development capabilities coupled with state-of-the-art production facilities, Dottikon caters to bespoke needs, from initial developmental scales to full-fledged commercial production runs. The trust and collaboration between Dottikon and its clients are pivotal, as the company becomes an indispensable partner in the clients’ supply chain. As the pharmaceutical sector continues to evolve and demand for specialized molecules increases, Dottikon’s focus on exclusivity and expertise positions it well within the industry, ensuring steady demand and solidifying its role as a reliable, albeit lesser-known, catalyst in advancing pharmaceutical innovations.

DESN Intrinsic Value
235.91 CHF
Overvaluation 32%
Intrinsic Value
Price

See Also

What is Dottikon Es Holding AG's Operating Income?
Operating Income
137.1m CHF

Based on the financial report for Sep 30, 2025, Dottikon Es Holding AG's Operating Income amounts to 137.1m CHF.

What is Dottikon Es Holding AG's Operating Income growth rate?
Operating Income CAGR 10Y
35%

Over the last year, the Operating Income growth was 62%. The average annual Operating Income growth rates for Dottikon Es Holding AG have been 21% over the past three years , 26% over the past five years , and 35% over the past ten years .

Back to Top